Atorvastatin and Pravastatin Elevated Pre-heparin Lipoprotein Lipase Mass of Type 2 Diabetes with Hypercholesterolemia

Kei Endo; Yoh Miyashita; Atsuhito Saiki; Tomokazu Oyama; Nobukiyo Koide; Hiroshi Ozaki; Masaki Otsuka; Yoshiaki Ito; Kohji Shirai

doi:10.5551/jat.11.341

Original Articles

Atorvastatin and Pravastatin Elevated Pre-heparin Lipoprotein Lipase Mass of Type 2 Diabetes with Hypercholesterolemia

Kei Endo, Yoh Miyashita, Atsuhito Saiki, Tomokazu Oyama, Nobukiyo Koide, Hiroshi Ozaki, Masaki Otsuka, Yoshiaki Ito, Kohji Shirai

Author information

Kei Endo
The Center of Diabetes, Endocrine and Metabolism, Sakura Hospital, Toho University School of Medicine, Chiba, Japan
Yoh Miyashita
The Center of Diabetes, Endocrine and Metabolism, Sakura Hospital, Toho University School of Medicine, Chiba, Japan
Atsuhito Saiki
The Center of Diabetes, Endocrine and Metabolism, Sakura Hospital, Toho University School of Medicine, Chiba, Japan
Tomokazu Oyama
The Center of Diabetes, Endocrine and Metabolism, Sakura Hospital, Toho University School of Medicine, Chiba, Japan
Nobukiyo Koide
The Center of Diabetes, Endocrine and Metabolism, Sakura Hospital, Toho University School of Medicine, Chiba, Japan
Hiroshi Ozaki
The Center of Diabetes, Endocrine and Metabolism, Sakura Hospital, Toho University School of Medicine, Chiba, Japan
Masaki Otsuka
The Center of Diabetes, Endocrine and Metabolism, Sakura Hospital, Toho University School of Medicine, Chiba, Japan
Yoshiaki Ito
The Center of Diabetes, Endocrine and Metabolism, Sakura Hospital, Toho University School of Medicine, Chiba, Japan
Kohji Shirai
The Center of Diabetes, Endocrine and Metabolism, Sakura Hospital, Toho University School of Medicine, Chiba, Japan

Keywords: HMG-CoA reductase inhibitor, Pleiotropic effect, Type 2 diabetes mellitus, Hypercholesterolemia, Preheparin LPL mass

JOURNAL OPEN ACCESS

2004 Volume 11 Issue 6 Pages 341-347

DOI https://doi.org/10.5551/jat.11.341

Details

Abstract

To clarify whether 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statin) increases lipoprotein lipase mass in preheparin plasma (preheparin LPL mass), we observed the change in preheparin LPL mass during administration of atorvastatin and pravastatin to type 2 diabetes mellitus patients with hypercholesterolemia. The subjects were randomly divided into two groups. One group was 24 patients given atorvastatin (10 mg/day), and the other was 23 patients given pravastatin (20 mg/day) for 4 months. After 4 months of administration, no significant change of HbA1c was observed. TC significantly decreased in the atorvastatin group compared to the pravastatin group. TG significantly decreased in the atorvastatin group. Low density lipoprotein cholesterol level significantly decreased in both groups (− 36.3%, p < 0.01 in atorvastatin, − 24.3%, p < 0.01 in pravastatin). Preheparin LPL mass slightly increased in both groups after 4 months of administration. Especially in patients who showed low preheparin LPL mass (less than 50 ng/ml) before statin administration, preheparin LPL mass significantly increased in both groups (+ 25.8% in the atorvastatin group, + 24.39% in the pravastatin group). These results suggested that administration of atorvastatin and pravastatin to type 2 diabetic patients with hypercholesterolemia increased serum preheparin LPL mass concentration. Especially, its effect was remarkable in patients who showed low preheparin LPL mass.

Corresponding author

Register with J-STAGE for free!